IMMUNE CHECKPOINT INHIBITORS
Immune Checkpoint Inhibitor–Related Adverse Cardiovascular Events in Patients With Lung Cancer
According to data from a retrospective, single cohort study of 252 patients with lung cancer who received immune checkpoint inhibitor (ICI) or non-ICI therapy, ICIs were not independently associated with an increased risk of major adverse cardiovascular events, and ICI-associated cardiotoxicity was associated with elevations in serum troponin and B-type natriuretic peptide, as well as combined immunotherapy with VEGF or tyrosine kinase inhibitors.
JACC: CardioOncologyMeet the Faculty
Videos
-
Immune Checkpoint Inhibitors Managing Cardiotoxicity Associated With Immune Checkpoint Inhibitor Therapy
-
Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors and Cardiotoxicity: Incidence and Patient Risk Factors
-
Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors and Cardiotoxicity: The Pharmacist Perspective
